Biomed Israel 2024’s Post

#BiomedIsrael continues to be the largest and most recognized platform in the life science industry. Dear friends & colleagues While the path may be fraught with challenges, our objectives remain unaltered: to create a space where ideas thrive, interpersonal connections flourish, and inspiration leads the way. In times of uncertainty, our determination to collaborate and solve global unmet needs serves as a beacon of hope and becomes our greatest strength. Read more >> https://bit.ly/3O8KroH Don’t miss this fantastic opportunity for maximum exposure and build lasting business opportunities! Exhibit at Biomed Israel 2024 ♦ Showcase Your Product/Technology in the Exhibition Area ♦ Generate New Leads ♦ Enhance Current Business Endeavors ♦ Gain Unlimited Potential for New Business Ventures ♦ Benefit from Marketing Targeted to the Industry's Audience ♦ Company Profile Featured on the Biomed Website and Conference related materials #BiomedIsreal #StartUp #Biomedical #AI #BioConvergence #BioFood #GeneTherapy #Robotics #DigitalHealth #InfectiousDisease #MedicalDevice #B2B #intercontinental

Wednesday July 24th, 8-9.30am PT. USA-UK-ANGELS: https://lnkd.in/gvjDPmkU A collection of British linked startups, either based in UK or by British educated or UK citizen founders. 8:10 - 8:25 AlgoDynamix: AlgoDynamix is a pioneer of behavioural-based price forecasting for the financial markets. 8:25-8:40 Lúnasa Space: Lúnasa is building enabling technologies for space infrastructure services, and in-space testbeds 8:40 - 8:55 Ani Biome: Ani Biome developed a machine learning architecture for non-invasive digital diagnostics and personalization of liquid fermented bioactives, AgeBiotics. 8:55 - 9:10 Oxford Drug Design: Oxford is a pre clinical therapeutics with distinctive GenAI drug discovery platform (SynthAI) overcomes inefficiency limitations of current methods and accelerates the potential impact for patients.

🚀 Exciting Opportunity for UK SMEs! 🚀 Innovate UK is investing up to £15 million in innovation projects to tackle significant health and healthcare challenges. UK-registered SMEs can apply for a share of this funding to develop groundbreaking solutions. From experimental evaluation to clinical trials and product development, this competition covers a wide range of innovative activities. 🤝MTIF is open to collaborating or supporting SME organisations within our research community. This scheme offers an exciting opportunity to create innovative solutions for the future of health care. If you are interested in partnering with MTIF on this exciting opportunity or featuring us as a subcontractor, please get in touch directly via MTIF@ntu.ac.uk 🔑 Key Competition Details: - Project Value: £150,000 to £4 million - Maximum grant request: £2 million - Collaborative projects: SMEs must cover at least 50% of total costs - Project duration: 6 to 36 months - Work must be carried out in the UK and results produced in or from the UK - Start date: 1 May 2025 - End date: 30 September 2028 Innovate UK’s portfolio approach ensures funding across diverse technologies and themes, including: - Advanced therapies (e.g., gene and cell therapies) - Biosciences - Preclinical technologies and drug discovery - Diagnostics, medical technology, and devices - Precision medicine, digital health, and more 💡 Learn more about the fund and apply via https://lnkd.in/e6wKQrR3 📅 Dont miss MTIF's Cell Gene Therapy event, where you can learn more about our translational research capabilities - https://lnkd.in/gdY62gNu #InnovateUK #HealthcareInnovation #SMEs #FundingOpportunity #UKInnovation #HealthTech #InnovationProjects #Research #Development

Wednesday July 24th, 8-9.30am PT. USA-UK-ANGELS: Online: Register here: https://lnkd.in/gvjDPmkU A collection of British linked startups, either based in UK or by British educated or UK citizen founders.8:10 - 8:25 AlgoDynamix: AlgoDynamix is a pioneer of behavioural-based price forecasting for the financial markets. 8:25-8:40 Lúnasa Space: Lúnasa is building enabling technologies for space infrastructure services, and in-space testbeds 8:40 - 8:55 Ani Biome: Ani Biome developed a machine learning architecture for non-invasive digital diagnostics and personalization of liquid fermented bioactives, AgeBiotics. 8:55 - 9:10 Oxford Drug Design: Oxford is a pre clinical therapeutics with distinctive GenAI drug discovery platform (SynthAI) overcomes inefficiency limitations of current methods and accelerates the potential impact for patients.

Benjamin Reinhardt from Speculative Technologies could not join us this year, but we received a very informative article from him on innovation systems in different industry sectors. Thank you! In "Health technology is weird" he writes: "Health technology creates a self-reinforcing gravity well for funding, scientific, and metascientific interest". How can other urgent challenges develop similarly connected dynamics for new innovative products and startups? Each sector has different rules for growth. Innovation policies need to consider how to optimize and interconnect each sector. How can innovation ecosystems translate some of the findings to move more resources to similar challenges? Here is the article: https://lnkd.in/e6emcsZn #sciencefiction #tech4hope #pharma #aerospace #newmaterials #greenchemistry #humanhealth #planetaryhealth #innovationecosystems #deeptech #biotech #sciencepreneurs

📍 The relevance of the #BioRegionCatalonia in the development of advanced and emerging therapies 👇 📰 Scientific publications: #Catalonia stands 3️⃣rd position in Europe in publications about #ATMPs, trailing only Switzerland and the Netherlands. Institutions such as the Universitat de Barcelona, Hospital Clínic de Barcelona, the Universitat Autònoma de Barcelona, the Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), the Vall d'Hebron Barcelona Hospital Campus, or Bellvitge Biomedical Research Institute - IDIBELL are leading the ranking in terms of number of publications (2013-2022). ✍️ Catalonia also leads in the number of #patents for #AdvancedTherapies. Catalonia comes 6️⃣th (per million inhabitants) in Europe. ICREA - Institució Catalana de Recerca i Estudis Avançats, the UAB, and the UB, as well as companies like ESTEVE, GENTEC Pharmaceutical Group, OneChain Immunotherapeutics, and SpliceBio, are among those submitting patent applications for new inventions. 📋 Check the #BioRegionReport https://report.biocat.cat/ Promoted by: Biocat, BioRegion of Catalonia With the support of: Amgen, Almirall, AstraZeneca, Cuatrecasas, ESTEVE, and Sanofi In collaboration with: CataloniaBio & HealthTech, ACCIÓ, Farmaindustria and Fenin, Federación Española de Empresas de Tecnología Sanitaria.

🚀 Day 7: Understanding the Core Customer and Value Proposition with Michio Painter, PhD from the UMZH Translational Medicine Accelerator (TMA)! 💡 Tomorrow, our BEI teams will focus on presenting: 1️⃣ Who is the core customer of their future product? 2️⃣ What huge problem does this customer face? 3️⃣ What is the #1 value proposition their solution offers? 💡 About the UMZH Translational Medicine Accelerator (TMA)💡 The TMA supports researchers & entrepreneurs to critically evaluate their translational ideas, sharpen those ideas towards a viable commercial product, and ultimately advance that product through a spinout or other partnerships. We are open to all lifescience researchers under UMZH which includes University of Zurich, ETH Zürich, and all affiliated hospitals.  🧬 Let's keep pushing innovation forward! 🔥 #healthcareinnovation #valueproposition #lifesciences #entrepreneurship #BEIprogram #UZH #ETH #USZ #biotech #medtech #digitalhealth

Many of the biggest recent scientific breakthroughs have emerged from the field of biotechnology: invisible cochlear implants, genome-edited crops, and vaccines for once-incurable diseases. Alex Zhavoronkov will be joining a panel of experts at the Fortune Innovation Forum on May 27 to find out what more could be possible. #BiotechnologyBreakthroughs #MedicalAdvancements #FortuneInnovationForum #ExpertPanel #FutureTech

Graduated from the University of Ottawa in Civil Engineering! In 1979